Review of the Antifungal Drug Luconazole for the Treatment of Skin Infections

ARCHANA SANKHWAR; Shruti Khare

Abstract

Many U.S. researchers are still working on a broad-spectrum imidazole antifungal called Luliconazole to treat dermatophytic skin and nail infections. The in vitro activity of luliconazole against filamentous fungi, including dermatophytes, is among the highest of any antifungal drug tested to date. The unique molecular characteristics of a 10% solution of Luliconazole make it possible for the drug to quickly reach fungicidal concentrations in the nail unit, allowing it to permeate the nail plate. Given these characteristics, luliconazole is an effective medication for treating onychomycosis. This essay will discuss the history of luliconazole solution, 10% of its molecular characteristics, preclinical and clinical data, and its potential use in the future treatment of fungal infections. Dermatophytic skin and nail infections are being treated in the United States using luconazole, a new, broad-spectrum imidazole antifungal. Among the most effective antifungal medicines in vitro, luliconazole is effective against dermatophytes and other filamentous fungi. With its special molecular characteristics, a 10% solution of luliconazole can quickly reach fungicidal levels in the nail unit and penetrate the nail plate. Onychomycosis is effectively treated with luliconazole due to its powerful characteristics. Future prospects for the treatment of fungal infections are discussed, along with the history of luliconazole solution (10%), its molecular characteristics, preclinical data, and clinical data.